Drug Profile
Ocrelizumab - Biogen/Genentech
Alternative Names: 2H7-monoclonal-antibody; 2nd Generation Anti-CD20; Anti-CD20 monoclonal antibody - Genentech; Humanised Anti-CD20 mAb; Monoclonal-antibody-2H7; OCR; OCRE; Ocrevus; Ocrevus SC; PRO 70769; R 1594; RG 1594; rhuMab 2H7; RO4964913Latest Information Update: 14 Mar 2024
Price :
$50
*
At a glance
- Originator Biogen Idec; Genentech
- Developer Biogen; Biogen Idec; Chugai Pharmaceutical; Genentech; Roche
- Class Anti-inflammatories; Antineoplastics; Antirheumatics; Eye disorder therapies; Monoclonal antibodies; Urologics
- Mechanism of Action Antibody-dependent cell cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Multiple sclerosis
- Discontinued Eye disorders; Haematological malignancies; Lupus nephritis; Rheumatoid arthritis; Systemic lupus erythematosus
Most Recent Events
- 31 Dec 2023 Preregistration for Multiple sclerosis in United Kingdom (SC) before December 2023
- 12 Dec 2023 Hoffmann-La Roche initiates enrollment in a phase III GAVOTTE trial for Multiple sclerosis in Argentina, Belgium, Brazil, Bulgaria, Canada, Denmark, Germany, Greece, Italy, Mexico, Peru, Poland, Puerto Rico, Russian Federation, Switzerland, Turkey, Ukraine (IV) prior to December 2023 (NCT04548999)
- 30 Nov 2023 Preregistration for Multiple sclerosis in USA (SC) in November 2023